| Literature DB >> 30120322 |
Valeria Lis Le Gall1, Guilherme Marcondes Klafke2,3, Tatiana Teixeira Torres4.
Abstract
The cattle tick Rhipicephalus microplus is one of the most important ectoparasites with great sanitary and economic impact for cattle rearing worldwide. Ivermectin is commonly used to control tick populations, but its use over the last 30 years has led to the development of resistant populations of R. microplus, and a concomitant loss of efficacy. In this context, we aimed to determine the metabolic mechanisms that contribute to ivermectin resistance in a resistant strain of this species. We performed lethal time bioassays with inhibitors of detoxifying enzymes and xenobiotic transporters (four detoxification pathways) using two strains of ticks: a susceptible strain, Mozo, and a resistant strain, Juarez. We used four inhibitors to test the involvement of different families of proteins responsible for detoxification of ivermectin, namely cytochrome P450, esterases, glutathione-S-transferase, and ATP Binding Cassette Transporters. We calculated the synergistic factor for each inhibitor and strain. To different degrees, all tested inhibitors altered the mortality rates in the strain Juarez, indicating that multiple mechanisms are responsible for the resistant phenotype. Detoxification mechanisms mediated by ABC transporters were observed to be the most important. Esterases, glutathione-S-transferases, and cytochrome-oxidases played less important roles in detoxification.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30120322 PMCID: PMC6097998 DOI: 10.1038/s41598-018-30907-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Lethal concentrations of 50 and 90% and resistance ratios of 14–21 days larvae of Mozo and Juarez strains of Rhipicephalus microplus, as determined by the larval immersion test.
| Strain | N | Slope ± SE | Chi-square | DF | H | LC50 (CI95%) µM | LC90 (CI95%) µM | RR50 (CI95%) | RR90 (CI95%) |
|---|---|---|---|---|---|---|---|---|---|
| Juarez | 4539 | 1.69 ± 0.08 | 136.6 | 31 | 4.41 | 9.79 (8.24–12.1) | 56.25 (37.74–101.31) | 6.86 (6.22–7.57) | 20.79 (16.52–26.17) |
| Mozo | 3474 | 4.62 ± 0.21 | 200.71 | 31 | 6.47 | 1.43 (1.25–1.59) | 2.71 (2.36–3.29) | — | — |
N = number of individuals; SE = standard error; DF = degrees of freedom; H = heterogeneity on the Chi-square goodness of fit test; LC = lethal concentration in µM; CI = confidence interval, RR = resistance ratio.
Figure 1Regression plots obtained for the assays carried out with the larvae of Mozo strain in the presence of the inhibitors piperonyl butoxide (PBO), S,S,S-tributyl phosphorotrithioate (DEF), and diethyl maleate (DEM). This test was carried out to determine the maximum concentration of inhibitors that could be used to test the enzymes. Curves were estimated using a generalised linear model (glm) with a binomial distribution and a “probit” link function. Mortality was modeled as a function of the log-transformed concentration of the inhibitor (in µM). Shaded areas represent 95% confidence intervals.
Lethal concentrations obtained from the bioassays carried out with the susceptible Mozo strain of Rhipicephalus microplus exposed to the synergists, piperonyl butoxide, S,S,S-tributyl phosphorotrithioate, and diethyl maleate.
| Inhibitor | N | Slope ± SE | Chi-square | DF | H | LC5 (CI95%) µM | LC50 (CI95%) µM |
|---|---|---|---|---|---|---|---|
| piperonyl butoxide | 1079 | 2.87 ± 0.14 | 123.41 | 13 | 9.49 | 1.29 (0.58–1.99) | 4.84 (3.59–6.19) |
| S,S,S-tributyl phosphorotrithioate | 2165 | 1.82 ± 0.19 | 85.33 | 12 | 7.11 | 5.36 (0.05–16.99) | 43.16 (10.01–69.16) |
| diethyl maleate | 1536 | 2.81 ± 0.11 | 117.21 | 16 | 7.33 | 68.92 (43.15–94.67) | 265.24 (213.61–329.29) |
N = number of individuals; SE = standard error; DF = degrees of freedom; H = heterogeneity on the Chi-square goodness of fit test; LC = lethal concentration in µM; CI = confidence interval.
Figure 2Mortality of the Mozo strain (susceptible) compared to that of the Juarez strain (resistant) exposed to 12 µM of ivermectin at different times. The Mozo strain presented 100% mortality rate at 240 minutes, whereas the Jurez strain presents only 40% mortality in the same period of time. Curves were estimated using a generalised linear model (glm) with a binomial distribution and a “probit” link function. Mortality was modeled as a function of the log-transformed time (in minutes). Shaded areas represent the 95% confidence intervals.
Figure 3Mortality of Mozo and Juarez strains exposed to ivermectin (IVM) and inhibitors at different times. When Juarez strain was exposed only to IVM, 40% mortality was observed, but under exposure to IVM along with one of the inhibitors, mortality increased. No differences were observed in the mortality of Mozo strain when exposed to IVM alone or in combination with any of the inhibitors, piperonyl butoxide (PBO), diethyl maleate (DEM), S,S,S-tributyl phosphorotrithioate (DEF), or cyclosporine A (CsA). When exposed to IVM along with with CsA, the mortality of Juarez strain reached 100%. This mortality was equal to that of the susceptible strain, Mozo, when exposed to IVM. Curves were estimated using a generalised linear model (glm) with a binomial distribution and a “probit” link function. Mortality was modeled a function of the log-transformed time (in minutes). Shaded areas represent 95% confidence intervals.
Results of the lethal time bioassays carried out with the Mozo (susceptible) and Juarez (resistant) strains of Rhipicephalus microplus exposed to ivermectin and synergists.
| Strain | Treatment | N | Slope ± SE | Chi- square | DF | H | LT50 (minutes) (CI95%) | SR (CI95%) |
|---|---|---|---|---|---|---|---|---|
| Juarez | Ivermectin 12 µM | 2971 | 0.98 ± 0.06 | 36.01 | 16 | 2.25 | 2166.7 (1564.7–3393.55) | — |
| +PBO | 2662 | 1.14 ± 0.06 | 55.05 | 16 | 3.44 | 902.44 (705.75–1231.65)* | 2.4 (1.83–3.16) | |
| +DEM | 2927 | 1.44 ± 0.07 | 131.52 | 16 | 8.22 | 693.02 (518.7–1030.11)* | 3.13 (2.41–4.05) | |
| +DEF | 2514 | 1.55 ± 0.07 | 76.81 | 16 | 4.8 | 309.2 (252.16–378.36)* | 7.01 (5.45–9.01) | |
| +CsA | 1638 | 2.29 ± 0.12 | 67.74 | 16 | 4.23 | 216.02 (175.19–258.71)* | 10.03 (7.8–12.89) | |
| Mozo | Ivermectin 12 µM | 1636 | 2.62 ± 0.14 | 257.37 | 16 | 16.09 | 120.36 (64.61–173.73) | — |
| +PBO | 1259 | 2.95 ± 0.19 | 227.68 | 16 | 14.23 | 129.05 (65.22–183.03) | 0.93 (0.81–1.08) | |
| +DEM | 1199 | 2.64 ± 0.17 | 63.98 | 16 | 3.99 | 100.13 (71.03–127.86) | 1.2 (1.02–1.42) | |
| +DEF | 1502 | 2.49 ± 0.12 | 35.927 | 16 | 2.25 | 70.94 (56.99–85.16) | 1.69 (1.45–1.99) | |
| +CsA | 1043 | 2.3 ± 0.14 | 104.1 | 16 | 6.51 | 113.37 (73.77–154.86) | 1.06 (0.9–1.25) |
N = number of individuals; SE = standard error; DF = degrees of freedom; H = heterogeneity on the Chi-square goodness of fit test; LT = lethal time in minutes, SR = synergism ratio, CI = confidence interval, *values significantly different from the LT50 calculated for the treatment with ivermectin only, within the tests for the same strain.